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a promising approach for the develop-
ment of new therapeutic interventions
against CD, especially if they can be se-
lectively targeted to the gut or lamina
propria. Furthermore, the findings might
also help to tackle a long-standing prob-
lem in the vaccine field. Oral vaccines
have considerable attractions in terms of
ease of administration but are constrained
by poor immunogenicity and induction of
tolerance by antigens delivered by this
route. Suppression of Treg cell induction
has been shown to enhance the efficacy
of vaccines delivered by parenteral routes
(Jarnicki et al., 2008). Therefore, suppres-
sion of Treg cell conversion by commen-
sal DNA or synthetic TLR9 agonists has
potential to reverse tolerance and
improve the immunogenicity of vaccines
delivered by the oral route.
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The CD8+ T cell responses to CMV gradually increase in magnitude over time—so-called memory ‘‘inflation.’’
In this issue of Immunity, Snyder et al. (2008) examine the dynamics of memory inflation and demonstrate
continuous turnover of inflating T cells, drawing on both memory cells and naive cells to replace them.Cytomegaloviruses are ubiquitous patho-
gens. Human CMV (HCMV) infects most
of the human population, usually asymp-
tomatically, and persists lifelong. The
cellular immune responses to HCMV are
vigorous and sustained—indeed they
tend to increase over time and may
come to dominate the peripheral blood
of healthy elderly donors (Khan et al.,
2002). They are also essential for viral
control, given that immunosuppression
for transplantation or as a result of human
immunodeficiency virus (HIV) infection
can lead to viral reactivation and severe
disease.
This host-virus balance has been stud-
ied by Snyder and colleagues (Snyder
et al., 2008, this issue of Immunity) with
the murine (MCMV) model, in which520 Immunity 29, October 17, 2008 ª2008 Ea key role for specific CD8+ T cell popula-
tions can be more precisely defined.
MCMV-specific CD8+ T cells may be
protective against disease—for example
in immunosuppressed mice, as shown
by the group of Reddehase (Holtappels
et al., 2000). In these experiments it was
noted that some CD8+ T cells populations
may be sustained or even increase over
time in the lung. In further experiments us-
ing MHC-peptide tetramers, a continuous
accumulation of virus-specific CD8+
T cells over time was noted in all or-
gans—a feature termed ‘‘memory infla-
tion’’ (Karrer et al., 2003). The expansion
of CMV-specific T cells in the elderly,
which appears to be rather similar, has
been implicated in immunosenescence,
and thus understanding how memorylsevier Inc.inflation is established may be important
in understanding the negative effects of
CMV infection on human longevity (Khan
et al., 2002).
CMVs are large viruses, with a number
of open reading frames, but memory infla-
tion is only seen for a small subset of
epitopes from CMV proteins. Previous
work by the group of Hill, preceding the
study of Snyder in this issue, has shown
that the CD8+ T cell response to acute
CMV infection may be broad (Munks
et al., 2006). As the virus establishes per-
sistence, the T cell response narrows to
focus on a smaller number of immunodo-
minant epitopes, and these T cell popula-
tions tend to inflate. In contrast, T cells
specific for many of the acute-phase epi-
topes show a classical memory response,
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Previewswith a large early frequency peak that
declines to a long-term low-frequency
population. It is still not clear what drives
the selection of the ‘‘inflationary’’ epi-
topes. In some cases, T cells responding
to genes expressed under the imm-
ediate-early promotor may help provide
checkpoints to limit viral replication
(Simon et al., 2006). However, in general
it has been difficult to link immuno-
dominance with viral gene-expression
patterns, especially in human CMVs
(Sylwester et al., 2005), in which T cell re-
sponses to structural proteins that are not
under the immediate-early promotor
commonly dominate (Khan et al., 2002).
Even in MCMV, the fact that only one of
two epitopes from the same protein
(M38) is inflationary suggests factors
other than the kinetics of viral gene ex-
pression are involved (Munks et al., 2006).
CMV-specific responses that do not in-
flate have—despite the continuous pres-
ence of virus—a typical ‘‘central memory’’
profile of phenotype and function (Karrer
et al., 2003). They exhibit strong capacity
for lymph node homing, proliferation, and
cytokine secretion and sustain expres-
sion of costimulatory molecules such as
CD28 and CD27 and cytokine receptors
such as the IL7 receptor (CD127). In stark
contrast, ‘‘inflationary’’ CMV-specific
responses show an extreme of the ‘‘effec-
tor-memory’’ phenotype. These cells are
typically low in expression of molecules
associated with lymph node homing,
such as CCR7 and CD62L, and accumu-
late in many nonlymphoid organs. They
reduce expression of both CD28 and
CD27, lose expression of CD127, and ac-
quire expression of inhibitory receptors
such as CD85j and KLRG1. In humans,
these cells are often characterized as re-
expressing CD45RA, a marker normally
associated with naive cells (Appay et al.,
2002). Functionally, they are strong secre-
tors of antiviral cytokines such as IFN-g
and TNF-a and they maintain lytic capac-
ity. Importantly, this situation is quite
different from the ‘‘exhaustion’’ seen in
LCMV-specific CD8+ T cells in the face
of continuous viral replication.
Since the advent of MHC-peptide tetra-
mer staining, these striking CMV-specific
responses have attracted much attention
in ex vivo human studies. Early descrip-
tions of these cells, particularly those
that re-express CD45RA (effector
memory RA+ T cells or ‘‘TEMRA’’) havedescribed them as ‘‘late differentiated’’
or even ‘‘terminally differentiated.’’ It is
also known through a number of analyses
of TCR usage that individual clonotypes
may come to dominate the repertoire,
and thesemay persist over time (reviewed
inWaller et al., 2008). All of these pieces of
data had originally led to the impression
that the populations may represent an ac-
cumulation of highly differentiated cells,
with limited capacity for self-renewal.
However, this concept of a ‘‘terminally
differentiated’’ population has been chal-
lenged. In the MCMV model, analysis of
lymphnodes in particular revealed a resid-
ual ‘‘central’’ core of CD8+ T cells specific
for inflationary epitopes, undergoing
in vivo activation and turnover (Karrer
et al., 2003). More recently, studies in hu-
mans have shown that the expanded
TEMRA cell populationsmay regain prolif-
erative capacity and indeed may re-ex-
press lymph node homing markers and
costimulatory molecules upon appropri-
ate antigen re-encounter (Waller et al.,
2008).
So, if it occurs, how active is such turn-
over in vivo? To address this, Snyder
et al. (2008) have performed an elegant
set of experiments using adoptive transfer
of memory populations from different
stages of disease, coupled with analyses
ofproliferation in vivo. They transferred ‘‘in-
flationary’’ memory T cell populations into
infected recipients and controls and ana-
lyzed the fate of these cells. First, trans-
ferred memory cells can proliferate in vivo
within the new recipient—particularly if
theseare transferred fromrecently infected
mice. Even splenocytes transferred from
mice infected >3 months previously were
still able to proliferate when transferred
into chronically infected recipients. How-
ever, they did not accumulate. Because
the overall size of the memory population
changes little, these data indicated that
the population must turn over rapidly (esti-
mated half life of approximately 50 days).
If memory populations are relatively dy-
namic, to what extent might naive cells be
recruited in persistently infected mice to
maintain thispool?Snyder et al. (2008)per-
formed experiments in which the recipient
mice were treated with busulphan, a cyto-
toxic drug used in man in hematologic dis-
orders, to induce bone marrow suppres-
sion without killing established memory
T cells. Interestingly, upon adoptive trans-
fer of naive congenic cells, it was apparentImmunity 29that naive cells can be primed and ex-
panded in vivo, even in the presence of es-
tablished memory T cells specific for the
sameepitopes. Although this experimental
result is clear, it was also noted that thy-
mectomized mice infected with MCMV
(and without immunosuppression) may
also develop and sustain ‘‘inflationary’’
memory pools. Thus, although naive cells
cancontribute to themaintenanceofmem-
ory in certain settings, the exact require-
ment for this is not fully defined. Overall,
Snyder et al. (2008) conclude that a combi-
nation of naive cells and memory popula-
tions laid down early in infection may
sustainmemory inflation over time through
continuous renewal (Figure 1).
So is this the end of the road for the
terminal-differentiation hypothesis? A
number of questions remain unanswered.
In particular, how might such dynamics
play out inman, in which infection extends
over decades rather than weeks? One im-
plication of Snyder and colleagues’ data
is that there might be different phases of
memory maintenance with a particular
impact on dynamics of a thymic-output
decline in later life. One of the related les-
sons from this study for those analyzing
human infection is that it is still very diffi-
cult to draw precise conclusions about
the function and fate of cells on the basis
of their surface phenotypes, and current
linear-differentiation models need some
reassessment.
Other questions are more general. In
particular, how is the function of these
‘‘inflationary’’ cells maintained, in com-
parison to those of the intensively studied
LCMVmodel, in which chronic infection is
associated with progressive dysfunction
of CD8+ T cells? The dose of antigen
and the interval between re-encounters,
as well as the site of re-encounter, inflam-
matory environment and functionality of
CD4+ T cell populations may all differ,
but clearly over time, quite distinct pat-
terns of T cell development may emerge,
some of which are beginning to be dis-
sected in molecular terms. The extremely
long-term coevolution of mammals and
CMVs suggest that these pathogens
could have had a profound impact on
the programming of T cell behavior.
Finally, this study demonstrates that the
populations induced by CMV are large,
functional, dynamic and sustainable.
This is exactly what may be required in
a T cell-inducing vaccine for cancer or, October 17, 2008 ª2008 Elsevier Inc. 521
Immunity
PreviewsFigure 1. Evolution and Maintenance of Memory T Cell Memory after CMV Infection
The left-hand panels indicate two potential outcomes of CMV infection: The upper panel indicates conven-
tional memory responses, and the lower panel indicates ‘‘inflationary’’ responses. Over time, viral reacti-
vation events serve to restimulate the inflationary responses but not the classical memory responses. On
the right-hand side, for the noninflating response, the central memory pool (blue) is sustained at low levels
and enriched within lymphoid tissue. In the case of the inflating response, the situation is much more
dynamic. The large pools of differentiated cells found in blood and tissues (yellow) are turning over con-
tinuously, with some cells progressing to death, but with rapid resupply from self-renewing differentiated
cells, central memory pools, and naive (green) precursors.infection. Previous studies using recombi-
nant MCMVs have indicated that such
vectors can induce protective T cell re-
sponses against heterologous challenges522 Immunity 29, October 17, 2008 ª2008 Ewith vaccinia and LCMV (Karrer et al.,
2004). Even if the mechanisms that allow
this expansion of protective memory
require further definition, there exists anlsevier Inc.opportunity to harness this unique behav-
ior. Inflation may represent a threat for
economists, but immunologists may yet
learn to profit from it.
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